Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...
Rolling Out5d
What to know about the latest vaccine updates
COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...
Scientific American11d
A Vaccine for the Dreaded Norovirus Is Closer Than Ever
Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...
Investopedia on MSN7d
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
GlobalData on MSN11d
Moderna reports decline in Q4 2024 revenue
Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...
STAT4d
A small study on Covid vaccine safety sparks an online tempest
A small study on Covid vaccine safety has sparked an online tempest — and highlighted the conundrum faced by some scientists.
Health Minister Mark Butler tells Andrew Wilkie that local Moderna vaccination available mid year
Tasmanians are expected to be able to access a Moderna Covid vaccine manufactured in Australia later this year.